Home | Clinical Care | Research | Training | Division Activities

Education and Training:

B.S., Biology, Summa Cum Laude, Loyola University, Chicago, IL (1969)

M.D., University of Chicago, School of Medicine, Chicago, IL (1973)

Internship, University of California, San Francisco, CA (1973-74)

Residency I & 2, University of California, San Francisco, CA (1974-76)

Fellowship, Hematology, University of Washington, Seattle, WA (1976-78)

John M. Harlan, M.D.
Professor Emeritus of Medicine / Hematology
University of Washington

Associate Medical Director
Harborview Medical Center

Office Address:
Harborview Medical Center
Box 359756
Research & Training Building, Room 503c
300 Ninth Avenue
Seattle, WA 98104

Phone:  (206) 897-5314
Fax:      (206) 897-5312
E-mail:  jharlan@u.washington.edu


General hematology/oncology

Cancer care and training of specialists in resource-limited countries


Inflammation and apoptosis


Mechanisms of action of extracellular Bcl-2 protein in cytoprotection.

(of 200 total peer-review publications)

Vanasse GJ, Winn RK, Rodov S, Zieske AW, Li JT, Tupper JC, Tang J, Raines EW, Peters MA, Yeung KY, Harlan JM. Bcl-2 Overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and De novo Follicular Lymphoma. Mol Cancer Res. 2005; 2:620-31.

A Iwata, V Morgan-Stevenson, B Schwartz, Li Liu, J Tupper, X Zhu, J Harlan*, R Winn. Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury. PLoS ONE 2010:5(2): e9103. *co-senior and corresponding author

Iwata A, de Claro RA, Morgan-Stevenson VL, Tupper JC, Schwartz BR, Liu L, Zhu X, Jordan KC, Winn RK, Harlan JM. Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsis. PLoS One. 2011;6(2):e14729. PMID: 21390214.

de Claro RA, Zhu X, Tang J, Morgan-Stevenson V, Schwartz BR, Iwata A, Liles WC, RaineEW, Harlan JM. Hematopoietic Fas Deficiency Does Not Affect Experimental Atherosclerotic Lesion Formation despite Inducing a Proatherogenic State. Am J Pathol. 2011; 178(6):2931-7. PMID: 21550016